XML 25 R42.htm IDEA: XBRL DOCUMENT
v2.4.0.8

U.S. Government Agreement, Joint Venture and Collaborations (Details) (USD $) | 3 Months Ended | 9 Months Ended |  | 3 Months Ended | 9 Months Ended | 12 Months Ended | 44 Months Ended |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 27 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 Cadila [Member] | Sep. 30, 2014 HHS BARDA Contract [Member] | Sep. 30, 2014 HHS BARDA Contract [Member] | Dec. 31, 2012 HHS BARDA Contract [Member] | Sep. 30, 2014 HHS BARDA Contract [Member] | Feb. 28, 2011 HHS BARDA Contract [Member] | Sep. 30, 2014 HHS BARDA Option for Additional Period [Member] | Feb. 28, 2011 HHS BARDA Option for Additional Period [Member] | Feb. 28, 2011 License Agreement with LG Life Sciences, Ltd. [Member] | Dec. 31, 2013 PATH Vaccine Solutions [Member] | Sep. 30, 2014 PATH Vaccine Solutions [Member] | Sep. 30, 2014 PATH Vaccine Solutions [Member] | Sep. 30, 2014 PATH Vaccine Solutions [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contract receivable |  |  |  |  |  |  |  |  |  | $ 97,000,000 | $ 70,000,000 | $ 79,000,000 |  |  |  |  |
Government contracts | 7,504,000 | 4,268,000 | 20,217,000 | 10,985,000 |  | 7,500,000 | 20,000,000 |  | 72,000,000 |  |  |  |  |  |  |  |
Research and development collaborations | 710,000 | 534,000 | 3,718,000 | 1,182,000 |  |  |  |  |  |  |  |  |  |  | 100,000 | 2,000,000 | 5,800,000
Contract |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000 |  |  | 5,800,000
Trial costs incurred |  |  |  |  |  |  |  | 2,900,000 |  |  |  |  |  |  |  |  |
Upfront license payment |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,500,000 |  |  |  |
Ownership percentage | 20.00% |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Joint Venture Percentage Owned By Others |  |  |  |  | 80.00% |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Total clinical trial costs incurred. + References No definition available. + Details
Name: | nvax_ClinicalTrialCostsIncurred
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract + References No definition available. + Details
Name: | nvax_Contract
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of the joint venture owned by others. + References No definition available. + Details
Name: | nvax_JointVenturePercentageOwnedByOthers
Namespace Prefix: | nvax_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Research And Development Collaboration + References No definition available. + Details
Name: | nvax_ResearchAndDevelopmentCollaboration
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront License Payment + References No definition available. + Details
Name: | nvax_UpfrontLicensePayment
Namespace Prefix: | nvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_ContractsRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of receivables that are derived from government contracts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 310 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6471842&loc=d3e55295-109406 + Details
Name: | us-gaap_GovernmentContractReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant